Form 4: Centessa Pharmaceuticals Director Mary Lynne Hedley Granted 40,000 Stock Options

Centessa Pharmaceuticals plc director Mary Lynne Hedley was granted 40,000 stock options with an exercise price of $12.43, vesting based on continued service.

Summary

• Mary Lynne Hedley, a Director of Centessa Pharmaceuticals plc (CNTA), was granted 40,000 share options.
• The options have an exercise price of $12.43 per share.
• The grant date and date exercisable is June 20, 2025.
• The options expire on June 20, 2035.
• The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date (June 20, 2026) or the Issuer's next annual meeting of shareholders, contingent on continued service as a director.
• Each option represents the right to buy one Ordinary Share, which may be represented by American Depositary Shares (ADSs).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it represents a standard compensation practice that aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options to Director Mary Lynne Hedley aligns her interests with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long-term incentive.

Negatives

• Potential for future dilution if the options are exercised, though this is standard for equity compensation.

Risks

• The value of the options is dependent on the future stock price of Centessa Pharmaceuticals plc exceeding the exercise price of $12.43.
• Vesting is subject to continued service as a director, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The vesting schedule for the granted options, tied to continued service, indicates an expectation of Mary Lynne Hedley's ongoing commitment and contribution as a director to Centessa Pharmaceuticals plc for at least the next year or until the next annual meeting.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to align leadership interests with long-term shareholder value creation.

Comparison to Industry Standards

• This type of equity grant, specifically stock options with a vesting schedule, is a standard compensation mechanism for directors in publicly traded biotechnology and pharmaceutical companies.
• It is comparable to practices seen at companies like Moderna, BioNTech, or Regeneron, where equity incentives are used to attract and retain top talent and align their performance with company growth and shareholder returns.
• The specific exercise price and number of options would typically be benchmarked against peer group compensation data, though such comparative data is not provided in this filing.

Corporate Governance

Related Party Transactions

• The grant of 40,000 share options to Mary Lynne Hedley, a director of Centessa Pharmaceuticals plc, constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also improved alignment of director's interests with long-term shareholder value.
• Employees: No direct impact mentioned, but reflects the company's compensation philosophy.
• Director (Mary Lynne Hedley): Receives equity-based compensation, providing a direct financial incentive tied to the company's stock performance and continued service.

Next Steps

• Continued service of Mary Lynne Hedley as a director of Centessa Pharmaceuticals plc.
• Vesting of the 40,000 share options on the earlier of June 20, 2026, or the Issuer's next annual meeting of shareholders.
• Potential future exercise of the vested options by Mary Lynne Hedley.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, Stock Option Grant, Director Compensation, Insider Transaction, SEC Form 4, Equity Incentive, Pharmaceuticals, Biotechnology